Focal pancreatitis is a mass-like lesion resulting from acute or subacute inflammation in a limited region of the pancreas. Most commonly occurring in the pancreatic head, it poses a significant diagnostic challenge as it can mimic ductal adenocarcinoma. It may develop following an acute pancreatitis attack or on the background of chronic pancreatitis. The absence of vascular invasion, lack of upstream pancreatic atrophy, and clinical context play critical roles in differential diagnosis.
Age Range
30-70
Peak Age
50
Gender
Male predominant
Prevalence
Common
Focal pancreatitis results from a localized inflammatory process causing edema, cellular infiltration, and fibrosis in the pancreatic parenchyma. During acute pancreatitis, focal activation of proteolytic enzymes leads to peripancreatic fat necrosis and parenchymal damage. During healing, granulation tissue and fibrosis develop, creating a mass-like appearance. On imaging, it appears as a hypoattenuating/hypointense focal lesion because inflammatory-fibrotic tissue shows different vascular kinetics from normal acinar parenchyma — less enhancement early, increasing enhancement late. Importantly, since the desmoplastic reaction is not as intense as adenocarcinoma, there is no vascular invasion and 'double duct sign' (simultaneous pancreatic duct and CBD dilatation) typically does not occur. Peripancreatic inflammatory changes (fat stranding, fluid) accompany and this finding is not expected in neoplasm.
The main pancreatic duct traverses through the focal mass (with smooth or mildly narrowed caliber) to reach distal parenchyma. In adenocarcinoma, the duct is obstructed by the mass showing an abrupt cutoff, whereas in focal pancreatitis, although narrowed, the duct can be traced through the inflammatory area. This finding is best evaluated on MRCP and is strong evidence favoring inflammatory etiology.
A focal hypoattenuating area is seen in a segment of the pancreas (frequently the head) on arterial phase. It enhances significantly less than normal pancreatic parenchyma, creating a mass-like appearance. Borders are usually irregular and gradual.
Report Sentence
A focal hypoattenuating area with less enhancement than normal parenchyma is seen in the pancreatic head on arterial phase; focal pancreatitis or neoplastic process should be considered in the differential diagnosis.
Focal hypoattenuation persists on portal venous phase but the contrast difference with normal parenchyma may decrease. Fat stranding and minimal fluid may be seen in peripancreatic fat tissue.
Report Sentence
Focal hypoattenuation persists on portal venous phase with accompanying peripancreatic inflammatory fat changes.
On delayed phase, the focal inflammatory area shows progressive enhancement with the density difference from normal parenchyma decreasing or disappearing. This progressive enhancement pattern is less pronounced in adenocarcinoma.
Report Sentence
The focal area demonstrates progressive enhancement on delayed phase becoming isodense with normal parenchyma; this pattern may favor an inflammatory etiology.
On T2-weighted sequences, the focal inflammatory area appears mildly to moderately hyperintense compared to normal parenchyma. This hyperintensity indicates edema and active inflammation. Peripancreatic T2 hyperintense fluid/inflammation may accompany.
Report Sentence
A focal hyperintense area is seen in the pancreas on T2-weighted sequences, consistent with edema and an active inflammatory process.
On DWI, the focal inflammatory area may show mild to moderate diffusion restriction. However, the degree of restriction is generally milder than adenocarcinoma with higher ADC values.
Report Sentence
Mild diffusion restriction is seen in the focal area on DWI with ADC values not demonstrating marked decrease.
On B-mode ultrasonography, a focal hypoechoic area is seen in the pancreas. Borders may be irregular. Peripancreatic free fluid and increased echogenicity of fat tissue (inflammation) may accompany. CBD dilatation may be seen in head lesions.
Report Sentence
A focal hypoechoic area is seen in the pancreatic head which may be consistent with an inflammatory process in the clinical context; further characterization with CT/MRI is recommended.
On arterial phase, peripancreatic vascular structures (SMA, SMV, portal vein, splenic vein) are patent with normal caliber. There is no vascular invasion, occlusion, or tumor thrombus. This finding is important in differentiating from adenocarcinoma.
Report Sentence
Peripancreatic vascular structures (SMA, SMV, portal vein) are patent with normal caliber and no vascular invasion is identified.
Criteria
Focal pancreatic mass developing during or immediately after an acute pancreatitis attack, with prominent peripancreatic inflammatory changes and elevated lipase/amylase
Distinct Features
Prominent T2 hyperintensity (edema), peripancreatic fluid collections and fat stranding prominent, rapid clinical change. Resolution or significant shrinkage expected on follow-up CT/MRI at 4-8 weeks.
Criteria
Focal lesion persisting 2-8 weeks after acute attack, inflammatory findings beginning to decrease, granulation tissue and early fibrosis development
Distinct Features
T2 hyperintensity begins to decrease, delayed phase enhancement becomes more prominent (fibrosis development). Peripancreatic changes begin to organize. Size reduction may be observed but complete resolution has not yet occurred.
Criteria
Focal inflammatory change in the region between pancreatic head and duodenum, overlapping features with groove pancreatitis, alcohol history frequently positive
Distinct Features
Duodenal wall thickening and small cystic changes may accompany. Inflammatory changes at the minor papilla region. Shares common pathophysiological mechanisms with groove pancreatitis. CBD may show smooth narrowing at the distal segment.
Distinguishing Feature
Adenocarcinoma shows significant upstream pancreatic duct dilatation, parenchymal atrophy, vascular invasion (SMA/SMV/portal vein), abrupt duct cutoff ('double duct sign' in head lesions), and regional LAP. These findings are absent in focal pancreatitis; the pancreatic duct is smoothly narrowed and traceable distally ('duct-penetrating sign'), vascular structures are patent, and peripancreatic inflammatory changes accompany.
Distinguishing Feature
In AIP, capsule-like periparenchymal rim, diffuse sausage-shaped enlargement pattern, IgG4 elevation, and steroid response are distinguishing. In focal pancreatitis, history of acute pancreatitis, peripancreatic inflammatory changes, and absence of capsule-like rim are expected. AIP is T2 hypointense while focal pancreatitis is T2 hyperintense.
Distinguishing Feature
Neuroendocrine tumor demonstrates intense homogeneous arterial enhancement (hypervascular). Focal pancreatitis is hypoattenuating on arterial phase. NET is usually a well-defined round mass without accompanying peripancreatic inflammatory changes.
Distinguishing Feature
Chronic pancreatitis mass shows parenchymal calcifications, main duct dilatation, and chain-of-lakes pattern. In focal pancreatitis, calcifications and significant duct dilatation are absent; peripancreatic acute inflammatory changes are more prominent.
Urgency
urgentManagement
conservativeBiopsy
Not NeededFollow-up
6-monthThe most critical clinical significance of focal pancreatitis is differentiation from adenocarcinoma. History of acute pancreatitis, laboratory findings (elevated lipase/amylase, normal CA 19-9), and imaging features (absence of vascular invasion, peripancreatic inflammation, duct-penetrating sign) should be evaluated. If diagnostic uncertainty persists, EUS-FNA is recommended. Follow-up CT/MRI should be performed at 4-8 weeks to confirm lesion resolution or shrinkage. If size increase or new suspicious findings develop, adenocarcinoma should be reconsidered. Most focal pancreatitis resolves with conservative management.
Focal pancreatitis can mimic PDAC and differentiation is often challenging. Clinical context (acute abdominal pain, elevated enzymes) and follow-up imaging are important. EUS-guided biopsy may be necessary in equivocal cases.